Munish Gairola
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Munish Gairola has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Abhay Kumar Singh
Department of Physics, GLA University, Mathura, India
3 shared publications - Dipesh
Department of Physics, GLA University, Mathura, India
3 shared publications - Manindra Bhushan
Department of Radiation Oncology, Division of Medical Physics, Rajiv Gandhi Cancer Institute and Research Center, New Delhi, India
3 shared publications - Sandeep Singh
Department of Radiation Oncology, Amrita School of Medicine, Amrita Vishwavidyapeetham, Faridabad, India
3 shared publications - Benoy Kumar Singh
Department of Physics, Institute of Applied Science and Humanities, GLA University, Mathura 281406, India
2 shared publications - Supratik Sen
Department of Radiation Oncology, Dr. B. Borooah Cancer Institute, Guwahati, India
2 shared publications
Latest Publications
- 24 February 2026
- Published by Springer Nature in Physical and Engineering Sciences in Medicine
- Vol. 49 (2) , 1-13
Bridging precision and practice: dual validation of a high-resolution detector array for beam profiling and patient QA in robotic radiosurgery
This study assessed a high-resolution ionisation chamber-based PTW 1600SRS detector array (array) for beam profile analysis and patient-specific quality assurance (PSQA) in CyberKnife (CK) stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT). The goal was to determine its suitability for small fields and non-isocentric delivery, which is unique to robotic platforms. Detector performance was examined for dose linearity, reproducibility, beam profiles, output factors, dose-rate dependence, and verification of the Iris collimator field size. Results were benchmarked against diode-based commissioning data. Clinical applicability was tested by retrospectively verifying 20 intracranial SRS and 20 extracranial SBRT plans using gamma analysis with criteria ranging from 3%/3 mm to 1%/1 mm, as well as 4%/1 mm. The detector showed strong dose linearity (R2 = 0.999) and stable reproducibility. Beam profiles matched commissioning values within 0.5 mm, and output factors agreed within 2% for most collimators, with a maximum deviation of 3% at 5 mm. Dose-rate variation remained within 2.5% across relevant SADs. Iris collimator field sizes were consistent with reference measurements. Clinical validation achieved high passing rates, all with tolerance limit of > 95%. It enables accurate beam characterization and reliable PSQA in CK treatments. This work provides the first combined evaluation of beam analysis and clinical validation for this detector on a robotic radiosurgery system, supporting its routine use in small-field quality assurance.
- 24 February 2026
- Published by Springer Nature in Physical and Engineering Sciences in Medicine
- Vol. 49 (2) , 1-13
Bridging precision and practice: dual validation of a high-resolution detector array for beam profiling and patient QA in robotic radiosurgery
This study assessed a high-resolution ionisation chamber-based PTW 1600SRS detector array (array) for beam profile analysis and patient-specific quality assurance (PSQA) in CyberKnife (CK) stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT). The goal was to determine its suitability for small fields and non-isocentric delivery, which is unique to robotic platforms. Detector performance was examined for dose linearity, reproducibility, beam profiles, output factors, dose-rate dependence, and verification of the Iris collimator field size. Results were benchmarked against diode-based commissioning data. Clinical applicability was tested by retrospectively verifying 20 intracranial SRS and 20 extracranial SBRT plans using gamma analysis with criteria ranging from 3%/3 mm to 1%/1 mm, as well as 4%/1 mm. The detector showed strong dose linearity (R2 = 0.999) and stable reproducibility. Beam profiles matched commissioning values within 0.5 mm, and output factors agreed within 2% for most collimators, with a maximum deviation of 3% at 5 mm. Dose-rate variation remained within 2.5% across relevant SADs. Iris collimator field sizes were consistent with reference measurements. Clinical validation achieved high passing rates, all with tolerance limit of > 95%. It enables accurate beam characterization and reliable PSQA in CK treatments. This work provides the first combined evaluation of beam analysis and clinical validation for this detector on a robotic radiosurgery system, supporting its routine use in small-field quality assurance.
- 31 December 2025
- Published by Elsevier in Physica Medica
- Vol. 141, 105711
Predicting patient setup shifts in daily radiotherapy using machine learning on phantom-based CBCT and kV/MV data
- 31 December 2025
- Published by Elsevier in Physica Medica
- Vol. 141, 105711
Predicting patient setup shifts in daily radiotherapy using machine learning on phantom-based CBCT and kV/MV data
- 18 August 2025
- Published by Springer Nature in Radiological Physics and Technology
- Vol. 18 (4) , 1055-1063
Impact of dynamic jaw width adjustment in tomotherapy on hippocampus sparing and treatment efficiency in whole-brain radiotherapy
The aim of this study is to evaluate the impact of dynamic jaw width adjustment in tomotherapy on hippocampal sparing, target dose conformity, and treatment efficiency in hippocampal-avoidance whole-brain radiotherapy (HA-WBRT), in accordance with RTOG 0933 guidelines. A retrospective study of 60 patients treated with HA-WBRT was conducted. CT-MRI fusion facilitated accurate hippocampal delineation. Treatment plans were created using Accuray Precision TPS and delivered on the Radixact Tomotherapy system with three jaw widths (1 cm, 2.5 cm, and 5 cm), fixed pitch (0.215), and modulation factor (3.0). The prescription dose was 30 Gy in 10 fractions. Evaluation metrics included PTV coverage (D98%, V95%, D2%, Dmax), homogeneity index (HI), conformity index (CI), hippocampal and lens doses, and beam-on time (BOT). Plan verification was performed with ArcCHECK using 3%/3 mm and 3%/2 mm gamma criteria. The 1 cm jaw achieved the best PTV coverage (D98% = 29.22 Gy, V95% = 98.71%), with HI = 0.09, CI = 0.99, and superior hippocampal sparing (Dmax = 14.91 Gy, Dmin = 7.57 Gy), but had the longest BOT (1165 s). Wider jaws (2.5 cm, 5 cm) reduced BOT (480 s, 280 s) but slightly compromised conformity and increased OAR doses, all within limits. Jaw width selection in Helical Tomotherapy influences dose distribution characteristics and treatment delivery efficiency in hippocampus-sparing WBRT. A 1 cm jaw width provides superior dosimetric conformity and enhanced hippocampal sparing, albeit at the cost of increased BOT. In contrast, wider jaw widths (2.5 cm and 5 cm) improve delivery efficiency but result in modest reductions in dose precision and organ-at-risk sparing. Therefore, jaw width selection should be carefully individualized based on clinical objectives, balancing the trade-off between organ preservation and treatment efficiency.
- 18 August 2025
- Published by Springer Nature in Radiological Physics and Technology
- Vol. 18 (4) , 1055-1063
Impact of dynamic jaw width adjustment in tomotherapy on hippocampus sparing and treatment efficiency in whole-brain radiotherapy
The aim of this study is to evaluate the impact of dynamic jaw width adjustment in tomotherapy on hippocampal sparing, target dose conformity, and treatment efficiency in hippocampal-avoidance whole-brain radiotherapy (HA-WBRT), in accordance with RTOG 0933 guidelines. A retrospective study of 60 patients treated with HA-WBRT was conducted. CT-MRI fusion facilitated accurate hippocampal delineation. Treatment plans were created using Accuray Precision TPS and delivered on the Radixact Tomotherapy system with three jaw widths (1 cm, 2.5 cm, and 5 cm), fixed pitch (0.215), and modulation factor (3.0). The prescription dose was 30 Gy in 10 fractions. Evaluation metrics included PTV coverage (D98%, V95%, D2%, Dmax), homogeneity index (HI), conformity index (CI), hippocampal and lens doses, and beam-on time (BOT). Plan verification was performed with ArcCHECK using 3%/3 mm and 3%/2 mm gamma criteria. The 1 cm jaw achieved the best PTV coverage (D98% = 29.22 Gy, V95% = 98.71%), with HI = 0.09, CI = 0.99, and superior hippocampal sparing (Dmax = 14.91 Gy, Dmin = 7.57 Gy), but had the longest BOT (1165 s). Wider jaws (2.5 cm, 5 cm) reduced BOT (480 s, 280 s) but slightly compromised conformity and increased OAR doses, all within limits. Jaw width selection in Helical Tomotherapy influences dose distribution characteristics and treatment delivery efficiency in hippocampus-sparing WBRT. A 1 cm jaw width provides superior dosimetric conformity and enhanced hippocampal sparing, albeit at the cost of increased BOT. In contrast, wider jaw widths (2.5 cm and 5 cm) improve delivery efficiency but result in modest reductions in dose precision and organ-at-risk sparing. Therefore, jaw width selection should be carefully individualized based on clinical objectives, balancing the trade-off between organ preservation and treatment efficiency.
- Open Access
- 1 July 2019
- Published by Scientific Scholar
- Vol. 05 (02) , 041-043
Artificial Intelligence in Oncology: Potential and Pitfalls
Artificial intelligence (AI) has occupied the consciousness of successive generations of computer scientists, science fiction fans, and medical researchers alike, since the inception of the term in 1956.[1] The concept of AI as envisioned in popular culture is that of intelligent machines that can interpret the world as humans do, understand language, and learn from real world examples. While this specific vision of machines being able to replicate human thoughts, emotions, and reasons, remains for now in the realm of science fiction, narrower applications of AI that can perform specific tasks as good as humans are poised to transform medicine at the basic, clinical, management, and financial levels. Terminology surrounding these technologies continues to evolve and can often be a source of confusion for noncomputer scientists. [Fig. 1] provides a broad overview. Data science is the broad field within which the subfields of AI, machine learning (ML), and deep learning (DL) reside, with each successive layer adding more complexity than the former. ML employs algorithms which can learn complex relationships or patterns from empirical data and make accurate decisions without coding specific instructions to accomplish the assigned task.[2] The algorithm is “trained” using large volumes of data, which confer it the ability to “learn” how to perform the assigned task, under human supervision. In contrast, DL algorithms can be largely automatic once set in motion, learning intricate patterns from even raw data with minimal human intervention, and improving continuously.[3] The difference between the two is highlighted in [Fig. 2]. The potential and pitfalls of applying AI in oncology is exemplified by IBM’s Watson for Oncology (WFO) program, operated from Memorial Sloan Kettering Cancer Center (MSKCC) in New York and deployed in more than 230 hospitals across the world.[4] Initially, envisioned as a cloud based super-computer embedded with artificial intelligence, AI could shift through massive volume of data (from doctor’s notes to medical studies and clinical guidelines) to generate insights and identify, provocatively, new approaches to cancer care. However, till date, the only evidence, citing its capabilities, has focused on concordance analyses and demonstrated that it is competent (at best) in applying existing standard of care, not that it can improve them.[5] [6] Further shortcomings pertain to the training dataset being composed of synthetic cases rather than real world patients, resulting in treatment recommendations based on the preferences of a small subset of oncologists practicing at MSKCC.[6] In the current landscape of data science, it would be classified as a primitive form of ML. More sophisticated applications of AI are emerging at a rapid pace in all fields of medicine, and oncology is not an exception. These can be broadly classified into identification-, prediction- or discovery-focused applications of AI, and the distinction between them is often not clear. Identification-type applications can detect regions of interest (ROI; e.g., classification of moles on the basis of their malignant potential, malignant cells in histopathology images, or malignant appearing lesions on a radiological imaging modality such as mammogram/computed tomography [CT]/magnetic resonance imaging [MRI]) and classify these ROIs as malignant or benign.[7] [8] Prediction-focused applications result in identification of features (derived from quantifiable measures of the patient as a whole, the tumor, the clinical care received, or any aspect thereof), which can determine an outcome of interest.[9] Finally, discovery-focused applications identify previously unknown patient subgroups based on outcomes, assist in drug design and modeling based on analyzing a multitude of omics datasets (useful in translation oncology).[10] While no oncological subspecialty is immune to the effects of wider AI integration in the near future, the earliest to be challenged will likely be diagnostic subspecialties, namely, pathology and radiodiagnosis, followed closely by imaging-based subspecialties, such as radiation oncology (including medical physics and dosimetry). The examples cited here are an introductory representation of the potential applications of AI and a full review of the same is beyond the scope of this article. It is a foregone conclusion that the impending future of AI integration into oncological practice will be met with either resistance or enthusiasm from practitioners. Gazing into the crystal ball, one can envision an optimized health care delivery system in which patient care plans would be generated by algorithmically driven software and subsequently refined by oncologists based on their patient outcomes to maximize clinical benefit. Delivery of care would then be managed by a tiered team of clinicians based on their expertise. This human–machine symbiosis has been termed the centaur model.[11] A key barrier to adoption will be the “black-box” effect, which is the inability of AI algorithms to explain their predictions.[12] In all fairness, oncologists are also unable to perfectly explain their own judgments, which may be based on experience/intuition and the associated cognitive biases, but as new technology, the burden of proof is on AI to account for its predictions. Taking this argument one step further, if oncologists do not understand why the algorithm recommended a particular line of management, then why should patients trust the recommendation? Taken to the extreme, who is ultimately responsible for an algorithmic error in diagnosis or treatment? The doctor or the data scientist? The application of AI in oncology holds tremendous potential and, although it still remains to be explored fully, the benefits cannot be ignored. However, as clinicians we also have every right to be skeptical of inscrutable algorithms, and if they are...
- 1 July 2019
- Published by Scientific Scholar
- Vol. 05 (02) , 041-043
Open AccessArtificial Intelligence in Oncology: Potential and Pitfalls
Artificial intelligence (AI) has occupied the consciousness of successive generations of computer scientists, science fiction fans, and medical researchers alike, since the inception of the term in 1956.[1] The concept of AI as envisioned in popular culture is that of intelligent machines that can interpret the world as humans do, understand language, and learn from real world examples. While this specific vision of machines being able to replicate human thoughts, emotions, and reasons, remains for now in the realm of science fiction, narrower applications of AI that can perform specific tasks as good as humans are poised to transform medicine at the basic, clinical, management, and financial levels. Terminology surrounding these technologies continues to evolve and can often be a source of confusion for noncomputer scientists. [Fig. 1] provides a broad overview. Data science is the broad field within which the subfields of AI, machine learning (ML), and deep learning (DL) reside, with each successive layer adding more complexity than the former. ML employs algorithms which can learn complex relationships or patterns from empirical data and make accurate decisions without coding specific instructions to accomplish the assigned task.[2] The algorithm is “trained” using large volumes of data, which confer it the ability to “learn” how to perform the assigned task, under human supervision. In contrast, DL algorithms can be largely automatic once set in motion, learning intricate patterns from even raw data with minimal human intervention, and improving continuously.[3] The difference between the two is highlighted in [Fig. 2]. The potential and pitfalls of applying AI in oncology is exemplified by IBM’s Watson for Oncology (WFO) program, operated from Memorial Sloan Kettering Cancer Center (MSKCC) in New York and deployed in more than 230 hospitals across the world.[4] Initially, envisioned as a cloud based super-computer embedded with artificial intelligence, AI could shift through massive volume of data (from doctor’s notes to medical studies and clinical guidelines) to generate insights and identify, provocatively, new approaches to cancer care. However, till date, the only evidence, citing its capabilities, has focused on concordance analyses and demonstrated that it is competent (at best) in applying existing standard of care, not that it can improve them.[5] [6] Further shortcomings pertain to the training dataset being composed of synthetic cases rather than real world patients, resulting in treatment recommendations based on the preferences of a small subset of oncologists practicing at MSKCC.[6] In the current landscape of data science, it would be classified as a primitive form of ML. More sophisticated applications of AI are emerging at a rapid pace in all fields of medicine, and oncology is not an exception. These can be broadly classified into identification-, prediction- or discovery-focused applications of AI, and the distinction between them is often not clear. Identification-type applications can detect regions of interest (ROI; e.g., classification of moles on the basis of their malignant potential, malignant cells in histopathology images, or malignant appearing lesions on a radiological imaging modality such as mammogram/computed tomography [CT]/magnetic resonance imaging [MRI]) and classify these ROIs as malignant or benign.[7] [8] Prediction-focused applications result in identification of features (derived from quantifiable measures of the patient as a whole, the tumor, the clinical care received, or any aspect thereof), which can determine an outcome of interest.[9] Finally, discovery-focused applications identify previously unknown patient subgroups based on outcomes, assist in drug design and modeling based on analyzing a multitude of omics datasets (useful in translation oncology).[10] While no oncological subspecialty is immune to the effects of wider AI integration in the near future, the earliest to be challenged will likely be diagnostic subspecialties, namely, pathology and radiodiagnosis, followed closely by imaging-based subspecialties, such as radiation oncology (including medical physics and dosimetry). The examples cited here are an introductory representation of the potential applications of AI and a full review of the same is beyond the scope of this article. It is a foregone conclusion that the impending future of AI integration into oncological practice will be met with either resistance or enthusiasm from practitioners. Gazing into the crystal ball, one can envision an optimized health care delivery system in which patient care plans would be generated by algorithmically driven software and subsequently refined by oncologists based on their patient outcomes to maximize clinical benefit. Delivery of care would then be managed by a tiered team of clinicians based on their expertise. This human–machine symbiosis has been termed the centaur model.[11] A key barrier to adoption will be the “black-box” effect, which is the inability of AI algorithms to explain their predictions.[12] In all fairness, oncologists are also unable to perfectly explain their own judgments, which may be based on experience/intuition and the associated cognitive biases, but as new technology, the burden of proof is on AI to account for its predictions. Taking this argument one step further, if oncologists do not understand why the algorithm recommended a particular line of management, then why should patients trust the recommendation? Taken to the extreme, who is ultimately responsible for an algorithmic error in diagnosis or treatment? The doctor or the data scientist? The application of AI in oncology holds tremendous potential and, although it still remains to be explored fully, the benefits cannot be ignored. However, as clinicians we also have every right to be skeptical of inscrutable algorithms, and if they are...